05 Март, 2003
New safety information associated with the use of ZOLOFT(tm) in patients taking pimozide
KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Canada Newswire English via NewsEdge Corporation : KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT (sertraline hydrochloride) capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Based on the result of a recent clinical study, the concomitant use of ZOLOFT and pimozide (an anti-psychotic medication) is now contraindicated. Patients are advised not to take ZOLOFT with pimozide as their interaction may result in arrhythmias (irregular heartbeats), which may be serious and life- threatening. Patients should be aware that the symptoms of possible arrhythmia include dizziness, palpitations and fainting, and that they should seek immediate medical attention if these symptoms occur. If you are presently being treated with this drug combination, please consult your physician before changing your current therapy. This advisory is in addition to a letter issued to health care professionals reminding them of the above-mentioned safety information. As well, the product monograph for ZOLOFT is being revised to inform physicians regarding potential adverse effects this drug combination may cause. If patients have questions regarding their current prescription, they are asked to contact their physician or pharmacist. VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=56403 -0- 03/05/2003 /For further information: please contact: Rhonda O'Gallagher, Senior Manager, Corporate Affairs, Pfizer Canada Inc., (514) 693-4090/ CO: ST: IN: SU: CNW 17:39e 05-MAR-03 <> << Copyright ©2003 Canada NewsWire >>
04 Март, 2003
Пополнение в разделе Пособия
04 Март, 2003
Современное учение о неврозах - Пауль Шильдер, Освальд Бумке

Современное учение о неврозах - Пауль Шильдер, Освальд Бумке

27 Февраль, 2003
Hersh & Hersh Targets Eli Lilly's Most Profitable Anti-Psychotic Drug
27/02/2003 - Hersh & Hersh Targets Eli Lilly's Most Profitable Anti-Psychotic Drug SAN FRANCISCO--(BUSINESS Representing Numerous Plaintiffs, Attorneys Aim to Enforce Prominent Labeling of Zyprexa's Acute Side Effects Business Wire via NewsEdge Corporation : SAN FRANCISCO--(BUSINESS WIRE)--Feb. 27, 2003-- Representing Numerous Plaintiffs, Attorneys Aim to Enforce Prominent Labeling of Zyprexa's Acute Side Effects Hersh & Hersh of San Francisco (www.hershlaw.com) today announced that it has already filed several complaints on behalf of plaintiffs across the U.S. against Indianapolis-based Eli Lilly & Co. Attorneys are in the process of filing numerous other complaints and plan to prove that as a result of taking Zyprexa, a drug prescribed for the treatment of schizophrenia and bipolar mania, their clients have sustained life-threatening or fatal injuries, including diabetes mellitus, hyperglycemia and pancreatitis. In some cases patients have died after long-term use of Zyprexa, even though it has been FDA-approved only as a short-term treatment, and their families have hired Hersh & Hersh to represent them in wrongful death suits against the giant drug manufacturer. Cases are being filed individually, in both Federal and State courts. According to Hersh & Hersh partner Nancy Hersh, "Eli Lilly's profits are skyrocketing from these 'atypical' anti-psychotic drugs, while patients are being kept in the dark about their damaging side effects. We believe Eli Lilly is culpable in heavily promoting Zyprexa as a safe and effective drug for psychotic disorders, yet virtually concealing the risks to doctors and their patients." Evidence of Fatal Side Effects Exposed Since 1996 Eli Lilly has widely promoted Zyprexa as the most effective medication on the market for bipolar disorder, with fewer adverse side effects than any other methods of treatment. It is also the company's top-selling drug, with reported sales of $3 billion in 2001. However in 2002, author of Mad In America and medical journalist Robert Whitaker exposed clinical trial data about Zyprexa that was not made available to most doctors prescribing the drug. According to Whitaker, "Of the 2,500 patients in the trials who received Zyprexa, 20 died; 20 committed suicide; and 22% suffered a 'serious' adverse event. Two-thirds of the Zyprexa patients did not successfully complete the trials..." In July 2002, a team of medical researchers at Duke University discovered the link between the new generation of anti-psychotic drugs like Zyprexa and early onset diabetes. They identified 289 cases of diabetes in patients who had been prescribed Zyprexa, stating, "Of the 289 cases of diabetes linked to the use of Zyprexa, 225 were newly diagnosed cases; 100 patients developed ketosis (a serious complication of diabetes); 22 people developed inflammation of the pancreas, a life-threatening condition; and 23 people died. Over 70% of these cases occurred within six months of starting the drug treatment." Numerous other medical studies have reported that Zyprexa can result in serious -- and oft-fatal -- diabetic diseases, caused by severe insulin deficiency. In one Hersh & Hersh case, the North Carolina plaintiff suffered a diabetic coma after taking Zyprexa for eight months, and had to have his left leg and right foot amputated. In spite of these dangerous side effects there is no warning in Zyprexa's product information to monitor blood glucose levels, or discontinue use if high blood sugar is noted or if the patient develops diabetes. Currently, the literature accompanying Zyprexa only alludes to diabetes and acidosis as part of a list of side effects that are purported to be very rare. In the early 1980s Hersh & Hersh began working on DES cases and was the first law firm in the Bay Area to successfully beat Eli Lilly on behalf of DES children. Today Hersh & Hersh is suing Eli Lilly for failing to adequately disclose the serious side effects of Zyprexa, and for not ameliorating the cause of these injuries even though they were "scientifically knowable" at the time of distribution. Off-Label Drug Use is Growing Problem Among the numerous cases to be filed by Hersh & Hersh attorneys, several individuals were prescribed Zyprexa for the treatment for "off label" symptoms, including anxiety and depression, even though it is FDA-approved exclusively for schizophrenia and bipolar disorder. At least one client so far has developed an irreversible neurological disorder known as Tardive Dyskinesia and is subjected to a life of repetitive, rhythmic involuntary movements such as tongue thrusting, lip smacking, chewing movements, rocking of the trunk, marching in place and repetitive sounds such as humming or grunting. Zyprexa is among a host of anti-psychotic drugs that doctors are encouraged to prescribe for off-label uses by manufacturers. According to an article published last summer in The Globe & Mail (August 13, 2002), medical ethics professor Miriam Shuchman, MD, stated that the biggest difference between the approved and unapproved use of a drug is the evidence that backs it up. To get a medical condition approved or "on-label," drug companies must convince the FDA that high-quality studies show that the drug makes a real difference for people with that condition. Off-label uses of a drug typically have not been subjected to that level of scrutiny. "To boost sales and circumvent the FDA approval process drug manufacturers like Eli Lilly are actually encouraging their sales reps to push secondary uses of these anti-psychotic drugs and regularly review reports of the frequency of doctors prescribing these meds for off-label uses," added Hersh. "In many cases, off-label sales account for the bulk of revenues generated by these drugs. Our intention in the case against Eli Lilly is to also shine a light on the severe damage caused by this kind of dubious sales and marketing practice." About Hersh & Hersh Hersh & Hersh is a San Francisco-based law firm dedicated to protecting the safety and rights of consumers. The law firm represents clients both on an individual level and in class and multi-district litigation, and has pursued and won a wide range of civil suits, from product liability, medical malpractice and insurance bad faith to sexual harassment and employee discrimination. For the past 32 years, Hersh & Hersh has been committed to using the law to protect individuals by making sure companies exercise due diligence in manufacturing their products and operate in good faith in delivering their services. CONTACT: Hersh & Hersh Shelly Gordon, 650/856-1607 (Press) sgordon g2comm.com or Lisa Byrne, 415/221-5018 (Press) lisa lisabyrne.com KEYWORD: NORTH CAROLINA INDIANA CALIFORNIA INDUSTRY KEYWORD: E-COMMERCE INTERNET LEGAL/LAW PHARMACEUTICAL GOVERNMENT CLASS ACTION LAWSUITS PRODUCT SOURCE: Hersh & Hersh Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com <> << Copyright ©2003 Business Wire >>
26 Февраль, 2003
Общая психопатология - Карл Ясперс
26 Февраль, 2003
7-я Междисциплинарная Региональная конференция по биологической психиатрии

Стресс и поведение

При поддержке International Brain Research Organisation (IBRO)

26-28 февраля 2003 г. в Москве состоится 7-я Междисциплинарная конференция по проблемам стрессорного поведения.

Цель ежегодной международной конференции, проводимой ЦФБП начиная с 1997 г собрать биологов, медиков и психологов из России и других стран СНГ для междисциплинарного обсуждения механизмов стрессорного поведения человека и животных в норме и патологии.

Темы конференции: нейрохимия и нейрофизиология поведения человека и животных, нейропсихофармакология, моделирование поведения, страх, тревога, депрессия, агрессия нейробиология и клинические аспекты, сон и его нарушения, механизмы памяти, психофизиология, нейропсихология, психиатрия, нейроэтология, этология человека

Подробная информация на веб-сайте конференции

E-mail: nem-physiol@mail.ru

Председатель конференции А.В.Калуев (Москва)
Председатель Программного комитета проф. О.Г.Сыропятов (Киев)

22 Февраль, 2003
FDA approves Prozac for use in children
LAHORE, Feb 20-PPI: Doctors can now prescribe the popular antidepressant Prozac to children suffering from depression and obsessive compulsive disorder, the US Food and Drug Administration has ruled, reports The HealthScout News Service. Pakistan Press International via NewsEdge Corporation : LAHORE, Feb 20-PPI: Doctors can now prescribe the popular antidepressant Prozac to children suffering from depression and obsessive compulsive disorder, the US Food and Drug Administration has ruled, reports The HealthScout News Service. The decision which covers children and teens seven to 17 years of age, marks the first approval of one of the newer types of antidepressants -called selective serotonin reuptake inhibitors, or SSRIs- or treating depression in children. Depression affects upto 25 per cent of children and about eight percent of teens in the United States. Obsessive Compulsive Disorder, or OCD, affects about tow percent o the population, and typically begins during adolescence or childhood. At least one-third of the cases of adult OCD begin in childhood, the National Institute of Mental Health says. Clinical trials revealed that the side effects of Prozac use in children and teens were similar to those typically experienced by adults, including nausea, tiredness, nervousness, dizziness, and difficulty concentrating, the FDA says. However, one trial in children and adolescents eight to 17 years old found that after 19 weeks of treatment with Prozac, the study participants gained, on average, about a half an inch less I height and about two pounds less in weight compared to children taking a placebo. The drug's maker, Eli Lilly, has agreed to conduct a follow up study to further evaluate any potential impact of Prozac's use on long-term growth in children, the FDA says. (THROUGH ASIA PULSE) 20-02 2003 <> << Copyright ©2003 Asia Pulse Pte Ltd. >>
20 Февраль, 2003
Cовременные аспекты клинической, экспертной и социальной проблем подростково-юношеской психиатрии

Программа постоянно действующего семинара по теме: "Современные аспекты клинической, экспертной и социальной проблем подростково-юношеской психиатрии" для психиатров, участвующих в военно-врачебной экспертизе, подростковых психиатров и психологов на 2003 год (восьмой год обучения)














    №№ пп

    Дата проведения

    Программа семинара

    Время проведения

    Руководитель семинара


    20.02.03 г.

    Психосоматические расстройства у детей и подростков


    Северный Анатолий Алексеевич к.м.н., ст.н.с. НЦПЗ РАМН


    20.03.03 г.

    Психология агрессивного поведения у подростков и юношей


    Ениколопов Сергей Николаевич Зав.отделом, к.п.н. НЦПЗ РАМН


    17.04.03 г.

    Объем понятия и критерии диагностики психопатии по данным катамнеза


    Ракитин Михаил Михайлович к.м.н., доцент кафедры психиатрии и наркологии фак-та постдипломного обучения Моск.Гос. медико-стоматологического университета


    15.05.03 г.

    Клиника и терапия агрессивного поведения у подростков


    Можгинский Юрий Борисович к.м.н., ассистент кафедры психиатрии и наркологии Моск. Гос. медико- стоматологического университета


    19.06.03 г.

    Наркомания в подростково- юношеском возрасте (особенности клиники, течения и лечения)


    Надеждин Алексей Валентинович к.м.н., главный детский нарколог МЗ РФ


    18.09.03 г.

    Роль родительско- семейных отношений в адаптации подростков и юношей с психическими расстройствами и задачи психолога и психиатра


    Чемекова Елена Борисовна научный сотрудник отдела клинической психологии НЦПЗ РАМН


    16.10.03 г.

    Умственная отсталость в подростково-юношеском возрасте (клинико-дифференциальная диагностика)


    Сухотина Нина Константиновна д.м.н., руководитель отделения клинико-психологических проблем нарушения психического развития НИИ психиатрии МЗ РФ


    19.11.03 г.

    Клиника и диагностика системных невротических и неврозоподобных расстройств у подростков


    Шевченко Юрий Степанович д.м.н., профессор, руководитель кафедры детской и подростковой психиатрии и психотерапии РМАПО


    11.12.03 г.

    Современные аспекты психофармакотерапии больных подростково-юношеского возраста


    Олейчик Игорь Валентинович к.м.н., ст.н.с. НЦПЗ РАМН Каледа Василий Глебович, к.м.н., ст.н.с. НЦПЗ РАМН



    Медицинское освидетельствование призывников в свете нового Положения о военно-врачебной экспертизе


    Фадеев Александр Сергеевич к.м.н., начальник отдела экспертизы военнослужащих ЦВВК МО

    Место проведения: Научный Центр психического здоровья РАМН (НЦПЗ РАМН), метро «Каширская», Каширское шоссе, 34 (авт.164, 220, 1 остановка) - конференцзал. Схема проезда.


    Главный научный сотрудник НЦПЗ РАМН
    Цуцульковская Мэлла Яковлевна
    Телефон 117-71-47

    Зав.Подростковым Центром
    Пыхтарев Валерий Николаевич
    Телефон 323-99-29, 324-41-05

    Вед.научный сотрудник НЦПЗ РАМН
    Симашкова Наталья Валентиновна
    Телефон 116-51-92
  • 19 Февраль, 2003
    Sales of Antipsychotics and Anticonvulsants for the Bipolar Drug Market Will Reach $2.6 Billion in 2011
    PR via NewsEdge Corporation : WALTHAM, Mass., Feb. 19 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales of antipsychotics and anticonvulsants for the bipolar drug market will reach $2.6 billion in 2011; this figure will represent nearly 90% of the total bipolar disorder drug market. (Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) "Growth in the on- and off-label use of antipsychotics and anticonvulsants will be the key market driver for the bipolar disorder drug market from 2001 through 2011," said Timothy Gasperoni, Ph.D., analyst at Decision Resources. "These agents will expand the range of therapeutic options for the short- and long-term treatment of manic and depressive symptoms -- particularly for the estimated 30-50% of patients who are unable to tolerate or fail to respond to lithium, the current standard of care." The new Pharmacor study entitled Bipolar Disorder also finds that Bristol- Myers Squibb's Abilify (aripiprazole) will spur market growth. "Despite its limited regulatory approval (i.e., for acute mania only) and its patent expiration in all markets in 2009, we expect Abilify to garner more than 11% of the bipolar disorder market in 2011," continued Dr. Gasperoni. Disease Background-Bipolar Disorder Bipolar disorder is a chronic and debilitating psychiatric illness characterized by recurrent episodes of aberrant mood. Mood episodes vary in duration among patients and feature symptoms of mania, depression, hypomania (a less severe form of mania), or a mixture of both depression and mania. Although more than 5 million people in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are afflicted with bipolar disorder, drug development for this indication has remained relatively stagnant. About Pharmacor from Decision Resources Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Bipolar Disorder is a Psychiatric Disorders study. About Decision Resources Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com. All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall dresources.com SOURCE Decision Resources, Inc. -0- 02/19/2003 /CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563, emarshall dresources.com/ /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION AP Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 212-782-2840/ CO: Decision Resources, Inc. ST: Massachusetts IN: MTC HEA PUB SU: SVY ES-CP -- NEW022 -- 5479 02/19/2003 10:37 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>
    18 Февраль, 2003
    Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT 7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided. European Patents via NewsEdge Corporation : Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT 7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided. Pub. No.: EP 1280781 Appl. Data: EP 01928857 2001 04 25 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Applicant: Bristol-Myers Squibb Co. << Copyright ©2003 MicroPatent >>